NCT03014089: A trial that was reported late by Moderna Therapeutics
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT03014089 |
|---|---|
| Title | A Phase 1/2, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 31, 2016 |
| Completion date | Sept. 30, 2018 |
| Required reporting date | Sept. 30, 2019, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 3, 2020 |
| Days late | None |